Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin and Fenofibrate Combination in Mixed Dyslipidemia
NCT02262143Phase 3Completed
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Nov 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenofibrate in mixed dyslipidemia (2 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoint: Mean percent change of Non-HDL Cholesterol at 8 weeks. Started Nov 2014; status: completed.
02
Drugs
fenofibrate
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT02262143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262143.